fda warning compounded semaglutide safety 2024 2025 Drug Recalls and Warnings: Recalls for and Tirzepatide, Wegovy; Facility Letters FDA warns consumers not to

For more information, book an appointment online or contact us

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

The official starting dose won't be confirmed until approval, but 2mg is most likely based on trial data, as it balances effectiveness with tolerability

At higher doses: Some participants experienced dysesthesia , an abnormal skin sensation Discontinuation rates were higher than placebo A portion of discontinuations were attributed to excessive weight loss , underscoring the importance of careful dosing and clinical oversight Additional late-stage trials are ongoing and will further clarify safety, tolerability, and optimal dosing strategies